What's Happening?
Norgine, a European specialty pharmaceutical company, has announced that its product PEDMARQSI (sodium thiosulfate anhydrous) has been registered by the Australian Therapeutic Goods Administration (TGA). This registration is for the prevention of ototoxicity
induced by cisplatin chemotherapy in children aged 1 month to under 18 years with localized, non-metastatic solid tumors. Cisplatin is a common chemotherapy drug that poses a risk of permanent hearing loss, which can significantly impact a child's development and quality of life. PEDMARQSI is the first treatment in Australia specifically approved to prevent this side effect. The approval is based on data from two Phase III clinical trials, SIOPEL 6 and COG ACCL0431, which demonstrated the safety and efficacy of the treatment.
Why It's Important?
The approval of PEDMARQSI in Australia addresses a significant unmet medical need for children undergoing cisplatin chemotherapy. Hearing loss in children can lead to long-term developmental challenges, affecting communication, education, and social interactions. By providing a preventive treatment, Norgine's PEDMARQSI offers a new option for healthcare providers to mitigate these risks, potentially improving the quality of life for affected children and their families. This development also highlights Norgine's capability to navigate complex regulatory pathways and expand the availability of specialized medicines across different regions.
What's Next?
Following the TGA approval, Norgine will focus on working with stakeholders to ensure access to PEDMARQSI for eligible patients in Australia. The company may also pursue inclusion of the treatment in the Pharmaceutical Benefits Scheme (PBS) to facilitate broader access. Additionally, Norgine's ongoing efforts to expand the reach of PEDMARQSI could lead to further regulatory approvals in other countries, enhancing its global impact on pediatric oncology care.
